Inotek Pharmaceuticals Corporation is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
“Inotek Pharmaceuticals Inc., a leader in the development of innovative products for the treatment of glaucoma, today announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma.” Read the following article
Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company’s product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. [Source: MarketWatch]
Company Website: http://www.inotekpharma.com